Lantheus Holdings, Inc. (LNTH) Stock Analysis
Last updated Oct 27, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 75
- Profitability 60
- Business Quality 75
- Balance Sheet 65
- Cash Flow 80
Why this rating?
Health 70/100 — High Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Lantheus Holdings, Inc. (LNTH) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Lantheus Holdings, Inc. 70/100 (High Quality) due to high business quality, steady revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Moderate
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 24.25
- Forward P/E 15.7
- EV/Revenue 4.21
Profitability
- Revenue Growth 2.7%
- Gross Margin 60.1%
- Operating Margin 25.8%
- Net Margin 17.7%
- ROE 22.2%
Financial strength
- Cash $593.30M
- Debt $624.96M
- Net Cash $-31.66M
- Free Cash Flow $348.64M
- Current Ratio 3.06
Similar companies
Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- United Therapeutics Corporation Drug Manufacturers - Specialty & Generic UTHR$591.20 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- BioCryst Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic BCRX$8.10 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Strong Entry Strong EntryTiming looks favorable across trend, momentum, valuation, support, and catalysts.
- Zoetis Inc. Drug Manufacturers - Specialty & Generic ZTS$78.23 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Neurocrine Biosciences, Inc. Drug Manufacturers - Specialty & Generic NBIX$146.00 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Strong Entry Strong EntryTiming looks favorable across trend, momentum, valuation, support, and catalysts.
- Trulieve Cannabis Corp. Drug Manufacturers - Specialty & Generic TRLV$10.67 64 Health 64 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Alkermes plc Drug Manufacturers - Specialty & Generic ALKS$44.32 62 Health 62 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Hims & Hers Health, Inc. Drug Manufacturers - Specialty & Generic HIMS$27.92 61 Health 61 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Teva Pharmaceutical Industries Limited Drug Manufacturers - Specialty & Generic TEVA$40.39 60 Health 60 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Lantheus Holdings, Inc. (LNTH).